Brown AND Burk Philippines Inc Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Brown AND Burk Philippines Inc Pharmaceutical Import Records from India — 2 Products, $887.9K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Brown AND Burk Philippines Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $887.9K Trade | TransData Nexus

Brown AND Burk Philippines Inc

Pharmaceutical Importer · Philippines · Diabetes & Endocrine Focus · $887.9K Total Trade · DGFT Verified

Brown AND Burk Philippines Inc is a pharmaceutical importer based in Philippines with a total trade value of $887.9K across 2 products in 1 therapeutic categories. Based on 25 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Brown AND Burk Philippines Inc sources from 1 verified Indian supplier, with Micro Labs Limited accounting for 100.0% of imports.

Brown AND Burk Philippines Inc — Import Portfolio & Supplier Network

Brown AND Burk Philippines Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Brown AND Burk Philippines Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Micro Labs Limited	$6.8M	303	100.0%

Brown AND Burk Philippines Inc sources from 1 verified Indian supplier across 289 distinct formulations. The sourcing is highly concentrated — Micro Labs Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Brown AND Burk Philippines Inc Import?

Formulation	Value	Ships
Melanov mr 60 ( (gliclazide 60MG	$100.0K	2
Melanov mr 60 (gliclazide 60MG tablets)	$87.2K	2
Melanov mr 60 ( (gliclazide modified-release 60MG tablets) ) ( 10x10s ) ( qty- 19757.000 )	$75.9K	3
Melanov mr 60 ( (gliclazide modified-release 60MG tablets) ) ( 10x10s ) ( qty- 19604.000 )	$75.0K	3
Q-win 100 (quetiapine fumarate tablets	$72.1K	2
Cetra tablets (paracetamol 325MG +	$69.1K	2
Carvidon-mr ( (trimetazidine hcl 35MG	$50.0K	1
Tripride 2 ( (glimepiride +	$50.0K	1
Citgo (citicoline tablets 500MG)	$50.0K	1
Prulibact (prulifloxacin 600MG tablets)	$50.0K	1
Askey cetirizine hcl BP 10MG	$50.0K	1
Syclop - 100 clozapine tablets USP	$50.0K	1
Askey 10 ( (cetirizine hydrochloride bp10mg tablets) ) ( 10x10s ) ( qty- 19233.000 )	$50.0K	1
Rispond-4 ( (risperidone tablets 4MG) )( 10s ) ( qty- 27991.000 )	$50.0K	1
Melanov mr 60 ( (gliclazide tablets 60MG	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Glimepiride	Diabetes & Endocrine	$460.0K	13	0.6%	12
2	Pioglitazone	Diabetes & Endocrine	$427.9K	12	1.1%	19

Brown AND Burk Philippines Inc imports 2 pharmaceutical products across 1 categories into Philippines totaling $887.9K.

Brown AND Burk Philippines Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Brown & Burk Philippines Inc. is a privately held pharmaceutical company headquartered in Makati City, Metro Manila, Philippines. Established on May 23, 2005, the company is dedicated to the professional and profitable distribution of pharmaceutical products within the country. Its mission is to provide Filipinos with international-quality medicines manufactured at US-FDA facilities, ensuring affordability and accessibility. The company emphasizes values such as integrity, excellence, discipline, fairness, and respect in its operations.

Brown & Burk Philippines Inc. operates as a pharmaceutical importer and distributor, focusing on branded generic pharmaceuticals. It collaborates with manufacturers like Micro Labs Limited, an Indian multinational pharmaceutical company, to source its product portfolio. The company markets its products to various healthcare professionals, including internists, family practitioners, general practitioners, psychiatrists, neurologists, gastroenterologists, endocrinologists, cardiologists, and specialists in otolaryngology, gynecology, and dermatology across the Philippines. (philjobnet.gov.ph)

2Distribution Network

Brown & Burk Philippines Inc. operates from its headquarters located at Unit 501, SEDCCO I Building, 120 Rada Street, Legaspi Village, Makati City, Metro Manila. (philjobnet.gov.ph) The company collaborates with distribution partners, such as RBC-MDC Corporation, to ensure its products reach a wide network of healthcare facilities, including leading chain pharmacies, independent pharmacies, private and government hospitals, and medical centers across the Philippines. (philjobnet.gov.ph) While specific details about its logistics capabilities and geographic coverage beyond the Philippines are not publicly disclosed, the company's extensive distribution network within the country indicates a robust logistics framework.

3Industry Role

In the Philippines' pharmaceutical supply chain, Brown & Burk Philippines Inc. functions primarily as a pharmaceutical importer and distributor. By sourcing branded generic pharmaceuticals from manufacturers like Micro Labs Limited, the company plays a crucial role in making these products accessible to a broad spectrum of healthcare providers and patients across the nation. Its focus on branded generics allows it to offer cost-effective alternatives to branded drugs, thereby enhancing the affordability and availability of essential medications in the Philippine market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Brown AND Burk Philippines Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Brown & Burk Philippines Inc. demonstrates a high degree of supplier concentration, sourcing its pharmaceutical products exclusively from Micro Labs Limited. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or quality control issues. However, the company's consistent importation of 25 shipments valued at $888,000 USD over the period from 2022 to 2026 suggests a stable and ongoing relationship with Micro Labs Limited. The substantial import value and frequency of shipments indicate a strong and reliable partnership, which may mitigate potential risks associated with supplier concentration.

2Supply Chain Resilience

The resilience of Brown & Burk Philippines Inc.'s supply chain is closely tied to its exclusive sourcing from Micro Labs Limited. While this concentrated sourcing strategy may expose the company to risks associated with supply chain disruptions, such as production delays or quality control issues, the consistent importation of 25 shipments valued at $888,000 USD over the period from 2022 to 2026 suggests a stable and ongoing relationship with Micro Labs Limited. This stability may help mitigate potential risks associated with supplier concentration. However, the lack of publicly available information regarding backup suppliers, formulation diversity, shipping route exposure, and the regulatory compliance status of Micro Labs Limited's facilities limits a comprehensive assessment of the supply chain's overall resilience.

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) is the primary regulatory body overseeing the importation, registration, and distribution of pharmaceutical products. The FDA operates under the Department of Health (DOH) and is responsible for ensuring the safety, efficacy, and quality of health products entering the country. Key legislation governing pharmaceutical imports includes the FDA Act of 2009 (Republic Act No. 9711) and the Food, Drugs, and Devices Act (Republic Act No. 3720). These laws establish the FDA's authority to regulate all health products, issue permits, licenses, and product registrations, and enforce standards for pharmaceutical imports. (respicio.ph)

2Import Licensing & GMP

Import licensing requirements in the Philippines stipulate that all pharmaceutical products must be registered with the FDA before they can be imported, sold, or distributed. The FDA requires a valid License to Operate (LTO) for importers and a Certificate of Good Manufacturing Practice (GMP) Compliance for manufacturers. GMP certificates from recognized authorities, such as the European Union (EU), World Health Organization (WHO), and Pharmaceutical Inspection Co-operation Scheme (PIC/S), are generally accepted by the FDA. Additionally, importers must secure the necessary import permits and clearances from the Bureau of Customs (BOC) prior to importation. (respicio.ph)

Brown AND Burk Philippines Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Brown & Burk Philippines Inc. focuses on therapeutic areas such as psychiatry, neurology, cardiology, endocrinology, antibiotics and analgesics, gastroenterology, and ophthalmology. This strategic focus aligns with the company's mission to provide Filipinos with international-quality medicines manufactured at US-FDA facilities at affordable prices. The emphasis on these therapeutic areas is driven by the market demand for effective treatments in these specialties, addressing prevalent health conditions in the Philippines. By concentrating on these segments, the company aims to meet the needs of healthcare professionals and patients, thereby enhancing its market presence and impact.

2Sourcing Profile

Brown & Burk Philippines Inc. employs a sourcing strategy that focuses on branded generic pharmaceuticals, primarily procuring products from Micro Labs Limited, an Indian multinational pharmaceutical company. This approach allows the company to offer cost-effective alternatives to branded drugs, enhancing the affordability and accessibility of essential medications in the Philippine market. The preference for branded generics aligns with the company's mission to provide international-quality medicines at affordable prices, ensuring that patients receive effective treatments without the high costs associated with branded pharmaceuticals.

Market Positioning

Seller's Guide — How to Become a Supplier to Brown AND Burk Philippines Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Brown & Burk Philippines Inc. to diversify its product offerings and reduce dependency on a single supplier. Establishing a relationship with Brown & Burk could involve demonstrating compliance with the Philippines' regulatory standards and offering competitive pricing to meet the company's quality and affordability criteria

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Brown AND Burk Philippines Inc

What products does Brown AND Burk Philippines Inc import from India?

Brown AND Burk Philippines Inc imports 2 pharmaceutical products across 1 categories. Top imports: Glimepiride ($460.0K), Pioglitazone ($427.9K).

Who supplies pharmaceuticals to Brown AND Burk Philippines Inc from India?

Brown AND Burk Philippines Inc sources from 1 verified Indian suppliers. The primary supplier is Micro Labs Limited (100.0% of imports, $6.8M).

What is Brown AND Burk Philippines Inc's total pharmaceutical import value?

Brown AND Burk Philippines Inc's total pharmaceutical import value from India is $887.9K, based on 25 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Brown AND Burk Philippines Inc focus on?

Brown AND Burk Philippines Inc imports across 1 categories. The largest: Diabetes & Endocrine (100.0%).

Get Full Brown AND Burk Philippines Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.